Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

27.3K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
27.3K
Adult Stem Cells01:33

Adult Stem Cells

33.4K
Stem cells are undifferentiated cells that divide and produce more stem cells or progenitor cells that differentiate into mature, specialized cell types. All the cells in the body are generated from stem cells in the early embryo, but small populations of stem cells are also present in many adult tissues including the bone marrow, brain, skin, and gut. These adult stem cells typically produce the various cell types found in that tissue—to replace cells that are damaged or to continuously...
33.4K
Embryonic Stem Cells00:58

Embryonic Stem Cells

32.1K
Embryonic stem (ES) cells are undifferentiated pluripotent cells, meaning they can produce any cell type in the body. This gives them tremendous potential in science and medicine since they can generate specific cell types for use in research or to replace body cells lost due to damage or disease.
32.1K
Embryonic Stem Cells00:57

Embryonic Stem Cells

4.8K
Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
4.8K
Multiple Allele Traits01:49

Multiple Allele Traits

38.0K
The Concept of Multiple Allelism
38.0K
Distinctive Features of Adult Stem Cells vs Cancer Stem Cells01:18

Distinctive Features of Adult Stem Cells vs Cancer Stem Cells

4.5K
A stem cell is an unspecialized cell that can divide without limit as needed and can, under specific conditions, differentiate into specialized cells.
Adult stem cells
Adult stem cells are tissue-specific; hence, they divide to develop the tissue from which they originate. One type of adult stem cell is the epithelial stem cell, which gives rise to the keratinocytes in the multiple layers of epithelial cells in the epidermis of the skin. Adult bone marrow has three distinct types of stem cells:...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of forced infusion in phacoemulsification training: a comparative study.

International ophthalmology·2026
Same author

Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in Sickle Cell Disease.

Blood·2026
Same author

Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.

Science translational medicine·2026
Same author

Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

CD19 CAR T-Cell Therapy for Treatment of Chronic Graft-versus-Host Disease.

The New England journal of medicine·2026
Same author

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Nature medicine·2026

Related Experiment Video

Updated: Jan 26, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

Allogeneic stem cell transplantation for multiple myeloma.

Roberto Bellucci1, Jerome Ritz

  • 1Center for Hematologic Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Reviews in Clinical and Experimental Hematology
|March 6, 2003
PubMed
Summary

Allogeneic stem cell transplantation (HSCT) effectively treats myeloma by enhancing chemotherapy and initiating an immune response against cancer cells. Donor lymphocyte infusions (DLI) show graft-versus-myeloma (GVM) effects but carry risks like graft-versus-host disease (GVHD).

More Related Videos

Transplantation of Tail Skin to Study Allogeneic CD4 T Cell Responses in Mice
06:48

Transplantation of Tail Skin to Study Allogeneic CD4 T Cell Responses in Mice

Published on: July 25, 2014

13.7K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.7K

Related Experiment Videos

Last Updated: Jan 26, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K
Transplantation of Tail Skin to Study Allogeneic CD4 T Cell Responses in Mice
06:48

Transplantation of Tail Skin to Study Allogeneic CD4 T Cell Responses in Mice

Published on: July 25, 2014

13.7K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.7K

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Myeloma cells' sensitivity to high-dose chemotherapy supports allogeneic hematopoietic stem cell transplantation (HSCT).
  • Allogeneic HSCT leverages both chemotherapy and an allogeneic immune response against residual myeloma cells.
  • Graft-versus-myeloma (GVM) effect is evidenced by donor lymphocyte infusion (DLI) responses in relapsed myeloma post-HSCT.

Purpose of the Study:

  • To explore the therapeutic potential of allogeneic HSCT in myeloma treatment.
  • To investigate the graft-versus-myeloma (GVM) effect mediated by donor lymphocytes.
  • To address toxicities associated with HSCT and DLI, and identify GVM target antigens.

Main Methods:

  • Analysis of allogeneic hematopoietic stem cell transplantation (HSCT) outcomes in myeloma patients.
  • Evaluation of donor lymphocyte infusion (DLI) efficacy in patients relapsed after HSCT.
  • Review of current research on reducing HSCT-related toxicities and enhancing GVM responses.

Main Results:

  • Allogeneic HSCT provides effective chemotherapy and induces an anti-myeloma immune response.
  • Donor lymphocyte infusion (DLI) demonstrates significant graft-versus-myeloma (GVM) activity in 30-50% of relapsed patients.
  • HSCT is associated with toxicities including graft-versus-host disease (GVHD) and infections; DLI can enhance immune reconstitution.

Conclusions:

  • Allogeneic HSCT is a viable myeloma treatment, offering both cytotoxic and immune-mediated anti-myeloma effects.
  • Donor lymphocyte infusion (DLI) can overcome relapse post-HSCT by leveraging the graft-versus-myeloma (GVM) effect.
  • Future research focuses on mitigating HSCT/DLI toxicities and optimizing GVM responses for improved myeloma management.